Over the trailing-12-month period, shares of French biotech Abivax (NASDAQ: ABVX) have skyrocketed by a little over 1,000%. The company has made tremendous progress with obefazimod, its leading pipeline candidate, which explains this performance. And even after this run, there might be significant upside left for the stock. Here are two reasons Abivax's stock could 10x over the next decade. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, cal ...

Core Viewpoint - Delek US Holdings, Inc. has demonstrated a significant turnaround in financial performance, reporting a strong earnings per share (EPS) and implementing strategic initiatives to optimize operations and improve cash flow [2][3][6] Financial Performance - The company reported an EPS of $1.26 for the quarter, surpassing the anticipated loss of $0.19 per share and improving from a loss of $2.54 per share in the same quarter last year [2][6] - Revenue for the quarter was approximately $2.43 billion, slightly below the expected $2.55 billion [2][6] - The Enterprise Optimization Plan has enhanced the company's cash flow profile and reduced costs related to Inventory Intermediation Agreements [3] Valuation Metrics - Delek US has a price-to-sales ratio of 0.21 and an enterprise value to sales ratio of 0.16, indicating a relatively low valuation compared to its sales [4] - The enterprise value to operating cash flow ratio stands at 3.26, reflecting a reasonable valuation based on cash flow [4][6] Dividend and Stock Performance - The company declared a quarterly dividend of 25.5 cents per share, and its stock price increased by 8.5%, closing at $36.38 [5] - Despite positive developments, an analyst maintained a Neutral rating on the stock, adjusting the price target from $42 to $38 [5] Debt and Liquidity - Delek US has a low debt-to-equity ratio of 0.15, indicating a low level of debt [5] - The current ratio of 0.82 suggests potential challenges in meeting short-term liabilities [5]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Ardent Health, Inc. securities between July 18, 2024, and November 12, 2025, of the March 9, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Ardent Health securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2] - The lead plaintiff must file a motion with the Court by March 9, 2026, to represent other class members in the litigation [2] Group 2: Law Firm Credentials - Rosen Law Firm specializes in securities class actions and has a strong track record, including the largest securities class action settlement against a Chinese company [3] - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [3] - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3] Group 3: Case Allegations - The lawsuit alleges that Ardent Health made misrepresentations regarding its accounts receivable and the processes used to determine their collectability [4] - Defendants claimed to employ an active monitoring process for accounts receivable, but the actual method involved a 180-day cliff for reserving accounts, leading to inflated reported amounts [4] - The firm also alleged that Ardent Health did not maintain sufficient professional malpractice liability insurance, which was inadequate to cover claims due to rising social inflationary pressures in medical malpractice cases [4]

Core Viewpoint - IonQ, Inc. (NYSE:IONQ) experienced a significant stock rally of over 20% following its earnings report, but the stock is currently trading lower, indicating a potential reversal in trend [1]. Price Dynamics - The price level of $41 has been identified as a critical point for IonQ, where a shift occurred from a downtrend to increased buying activity, halting the decline [2]. - Prior to the recent rally, IonQ shares were in a steep downtrend, with sellers needing to offer discounts to attract buyers, leading to an oversupply in the market [2]. - After the stock price fell below the $41 support level in January, many investors who had previously bought at that price began to regret their decisions, leading to a change in market sentiment [3]. Market Sentiment and Resistance - When IonQ's stock price returned to $41, many investors who had previously bought at that level placed sell orders, creating significant resistance due to the volume of these orders [4]. - The identification of key price levels, such as $41, is crucial for traders as it can lead to potential profits by understanding market dynamics [4].

By Echo Wang Feb 27 (Reuters) - A group of global investors including Qatar Holdings, an investment arm of Qatar Investment Authority, Visa and Abu Dhabi Investment Authority, is preparing to ‌invest more than $200 million as cornerstone investors in the U.S. initial public offering by SoftBank's ‌PayPay, according to two people familiar with the matter. PayPay, a Japanese digital payments provider, is targeting a valuation of up to $14 ​billion in the offering, one of the people said, in what could be ...

Core Viewpoint - LeMaitre Vascular (NASDAQ: LMAT) has shown significant stock performance, with shares increasing approximately 35% since June 2025, outperforming the broader market by more than double [1]. Financial Performance - The stock experienced a notable jump of around 20% following a strong Q4 earnings report, which included an upward revision of expectations for 2026 [1].

Core Viewpoint - PayPay, a Japanese digital payments provider, is preparing for an IPO in the U.S. with a target valuation of up to $14 billion, potentially marking the largest listing for a Japanese company on a U.S. stock exchange [2][7]. Group 1: IPO Details - A consortium of global investors, including Qatar Holdings, Visa, and Abu Dhabi Investment Authority, is set to invest over $200 million as cornerstone investors in PayPay's IPO [1]. - The IPO is planned for the Nasdaq next month, having been delayed from its initial December timeline due to a prolonged U.S. government shutdown affecting regulatory processes [3]. - PayPay aims to attract cornerstone investors to enhance the IPO's appeal [3]. Group 2: Financial Context - The IPO is crucial for SoftBank Group, which is heavily investing in artificial intelligence, having committed $30 billion to OpenAI and sold significant assets, including a $5.8 billion stake in Nvidia and $4.8 billion in T-Mobile U.S. shares [4]. - The PayPay listing could provide a timely cash boost for SoftBank, marking its first U.S. listing for a SoftBank-majority business since Arm Holdings [4]. Group 3: Company Background - PayPay was established in 2018 through a joint venture between SoftBank and Yahoo Japan, significantly contributing to Japan's digital transformation by promoting cashless payments [6]. - As of December 31, PayPay has approximately 72 million registered users, making it one of Japan's most widely used payment platforms [6][7]. - Recently, PayPay announced a partnership with Visa to facilitate its expansion into the U.S. market [5].

Group 1 - Investors are showing a bullish stance on Trip.com Group (NASDAQ: TCOM), with significant options trades indicating potential upcoming movements [1] - The sentiment among large traders is predominantly bullish at 80%, with only 10% bearish, highlighting a strong confidence in the stock [2] - The major market movers are focusing on a price range between $50.0 and $65.0 for Trip.com Group over the last three months, indicating expected price movements [3] Group 2 - Recent options activity shows a total trading volume of 1,938,767, with TCOM's price currently at $52.1, reflecting a 0.94% increase [6] - Analysts have set an average target price of $70.0 for Trip.com Group, with one analyst from Benchmark maintaining a Buy rating and a target price of $72 [5] - Another analyst from TD Cowen also maintains a Buy rating with a target price of $68, suggesting a consensus on the stock's potential [7]

Whales with a lot of money to spend have taken a noticeably bearish stance on Moderna.Looking at options history for Moderna (NASDAQ:MRNA) we detected 14 trades.If we consider the specifics of each trade, it is accurate to state that 35% of the investors opened trades with bullish expectations and 42% with bearish.From the overall spotted trades, 5 are puts, for a total amount of $180,802 and 9, calls, for a total amount of $512,400.Projected Price TargetsAnalyzing the Volume and Open Interest in these cont ...

In the current market session, Wynn Resorts Inc. (NASDAQ:WYNN) stock price is at $107.90, after a 2.12% drop. However, over the past month, the company's stock increased by 0.30%, and in the past year, by 21.19%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. A Look at Wynn Resorts P/E Relative to Its CompetitorsThe P/E ratio measures the current share price to the company's EPS. It is used by long-term inv ...